Abstract
Chemotherapy is widely used with surgery and radiotherapy for the treatment of malignant disease. Selectivity of most drugs for malignant cells remains elusive. Unfortunately, an insufficient therapeutic index, a lack of specificity, and the emergence of drug-resistant cell subpopulations often hamper the efficacy of drug therapies. Despite the significant progress achieved by chemotherapy in the treatment of disseminated malignancies, the prognosis for solid tumors remains poor. A number of specific difficulties are associated with the treatment of solid tumors, where the access of drugs to cancer cells is often limited by poor, unequal vascularization and areas of necrosis. The histological heterogeneity of the cell population within the tumor is another major drawback. Attempts to target therapies to tumors have been addressed by using prodrugs activated in tumors by elevated selective enzymes and are described in Chapter 27. An alternative strategy that use antibodies to target tumors with foreign enzymes that subsequently activate prodrugs is described in Chapter 26.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Marais, R., Spooner, R. A., Light, Y., Martin, J., and Springer, C. J. (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56, 4735ā4742.
Bridgewater, G., Springer, C. J., Knox, R., Minton, N., Michael, P., and Collins, M. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362ā2370.
Huber, B. E., Richards, C. A., and Austin, E. A. (1995) VDEPT; an enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Adv. Drug Delivery Rev. 17, 279ā292.
Eaton, J. L., Perry, M. J. A., Todryk, S. M., et al. (2001) Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther. 8, 557ā567.
Hermiston, T. (2000) Gene-delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest. 105, 1169ā1172.
Roth, J. A. and Cristiano, R. G. (1997) Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89, 21ā30.
Niculescu-Duvaz, I., Spooner, R., Marais, R., and Springer, C. J. (1998) Gene-directed enzyme prodrug therapy. Bioconj. Chem. 9, 4ā22.
Springer, C. J. and Niculescu-Duvaz, I. (1999) Patent property of prodrug involving gene therapy (1996ā1999). Exp. Opin. Ther. Patents 9, 1381ā1388.
Bilbao, G., Contreras, J. L., GĆ³mez-Navarro, J., and Curiel, D. T. (1998) Improving adenoviral vectors for cancer gene therapy. Tumor Target. 3, 59ā79.
Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L., and Terwilliger, E. F. (1998) Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor stratergy. Cancer Res. 58, 5673ā5677.
Robbins, P. D. and Ghivizzani, S. C. (1998) Viral vectors for gene therapy. Pharm. Ther. 80, 35ā47.
Zhang, W. W. (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 7, 113ā138.
Curiel, D. T., Gerritsen, W. R. and Krul, M. R. (2000) Progress in cancer gene therapy. Cancer Gene Ther. 7, 1197ā1199.
Roth, M. G. and Curiel, D. T. (2000) Toward the optimal vector for prostate cancer gene therapy; a CaPCURE meeting report. Cancer Gene Ther. 7, 1507ā1510.
Kirn, D. (2001) Clinical research results with dI 1520 (ONYX-015), a replication selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8, 89ā98.
Miller, A. D. (1998) Cationic liposomes for gene therapy. Angew. Chem. Int. Ed. 37, 1768ā1785.
Schatzlein, A. G. (2001) Non-viral vectors in cancer gene therapy: principles and progress. Anti-Cancer Drug Des. 12, 275ā304.
Springer, C. J. and Niculescu-Duvaz, I. (2000) Prodrug-activating systems in suicide gene therapy. J. Clin. Investig. 105, 1161ā1167.
Encell, L. P., Landis, D. M. and Loeb, L. A. (1999) Improving enzymes for gene therapy. Nature Biotechnol. 17, 143ā147.
Mesnil, M. and Yamasachi, H. (2000) Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communications. Cancer Res. 60, 3989ā3999.
Denny, W. A. and Wilson, W. R. (1998) The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme prodrugs therapies. J. Pharm. Pharmacol. 50, 387ā394.
Niculescu-Duvaz, I., Friedlos, F., Niculescu-Duvaz, D., Davies, L., and Springer, C. J. (1999) Prodrugs for antibody-and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anticancer Drug Des. 14, 517ā538.
Springer, C. J. and Niculescu-Duvaz, I. (2002) Gene-directed enzyme prodrug therapy, in Anticancer Drug Development (Baguley, B., ed.), Academic, New York, pp. 137ā135.
Marais, R., Spooner, R. A., Stribbling, S. M., Light, Y., Martin, J., and Springer, C. J. (1997) A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnol. 15, 1373ā1377.
Loimas, S., Toppinen, M.-R., Visakorpi, T., Janne, J., and Wahlfors, D. (2001) Human prostate carcinoma cells as target for herpes simplex virus thymidine kinase-mediated suicide gene therapy. Cancer Gene Ther. 8, 137ā144.
Jones, R. K., Pope, I. M., Kinsella, A. R., Watson, A. J. M., and Christmas, S. E. (2000) Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 7, 1519ā1528.
Walling, H. W., Swarthout, G. T., and Culver, K. W. (2000) Bystander-mediated regression of osteosarcoma via retroviral transfer of the herpes simplex virus thymidine kinase and human interleukin-2 genes. Cancer Gene Ther. 7, 187ā196.
Howard, B. D., Boenicke, L., Schniewind, B., Henne-Bruns, D., and Kalthoff, H. (2000) Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther. 7, 927ā938.
Sandmair, A.-M., Turunen, M., Tyynela, K., et al. (2000) Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther. 7, 413ā421.
Kruse, C. A., Lamb, C., Hogan, S., Russell Smiley, W., Kleinschmidt-DeMasters, B., and Burrows, F. G. (2000) Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther. 7, 118ā127.
Hamel, W., Zirkel, D., Mehdorn, H. M., Westphal, M., and Israel, M. A. (2001) E-5-(2-bromovinyl)-2ā²-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase-expressing cells. Cancer Gene Ther. 8, 388ā396.
Grignet-Debrus, C., Cool, V., Baudson, N., et al. (2000) Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2ā²-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-Ī²-d-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase. Cancer Gene Ther. 7, 215ā223.
Erbs, P., Regulier, E., Kintz, J., et al. (2000) In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60, 3813ā3822.
Bentires-Alj, M., Helin, A.-C., Lechanteur, C., et al. (2000) Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther. 7, 20ā26.
Spooner, R. A., Maycroft, K. A., Paterson, H., Friedlos, F., Springer, C. J., and Marais, R. (2001) Appropriate subcellular location of prodrug-activating enzymes has important consequences for suicide gene therapy. Int. J. Cancer 93, 123ā130.
Westphal, E.-M., Ge, J., Catchpole, J. R., Ford, M., and Kennedy, S. C. (2000) The nitroreductase/CB1954 combination in Eptein-Barr virus-positive B cell lines: induction of bystander killing in vitro and in vivo. Cancer Gene Ther. 7, 97ā106.
Tatcher, N. J., Edwards, R. J., Lemoine, N. R., Doehmer, J., and Davies, D. S. (2000) The potential of acetaminophen as a prodrug in gene-directed enzyme therapy. Cancer Gene Ther. 7, 521ā525.
Heine, D., Muller, R., and Brusselbach, S. (2001) Cell surface display of a lysosomal enzyme for extra-cellular gene-directed enzyme prodrug therapy. Gene Ther. 8, 1005ā1010.
Hamstra, D. A., Page, M., Maybaum, J., and Rehemtulla, A. (2000) Expression of endog-enously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-Ī±-peptide prodrugs. Cancer Res. 60, 657ā665.
Stribbling, S. M., Friedlos, F., Martin, J., et al. (2000) Regressions of established breast cancer xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Human Gene Ther. 11, 285ā292.
Greco, O., Folkes, L. K., Wardman, P., Tozer, G. M., and Dachs, G. U. (2000) Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther. 7, 1414ā1420.
Simonova, M., Wall, A., Weissleder, R., and Bogdanov, A. (2000). Tyrosinase mutants are capable of prodrug activation in transfected non-melanotic cells. Cancer Res. 60, 6656ā6662.
Kawamura, K., Tasaki, K., Hamada, H., Takenaga, K., Sakiyama, S., and Tagawa, M. (2000) Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity. Cancer Gene Ther. 7, 637ā643.
Cuq, P., Rouquet, C., Evrard, A., Ciccolini, J., Vian, L., and Cano, J.-P. (2001) Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase. Br. J. Cancer 84, 1677ā1680.
Weyel, D., Sedlacek, H. H., Muller, R., and Brusselbach, S. (2000) Secreted human Ī²-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 7, 224ā231.
Black, M. E., Newcomb, T. G., Wilson, H. M., and Loeb, L. A. (1996) Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA 93, 3525ā3529.
Black, M., Kokoris, M. S., and Sabo, P. (2001) Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61, 3022ā3026.
Blanche, F., Cameron, B., Couder, M., and Crouzet, J. (1997). Enzymes Combinations for Destroying Proliferative Cells, US Patent W09735024, Rhone-Poulenc Roerer, p. 1ā61.
Chen, L., Yu, L. J., and Waxman, D. J. (1997) Potentiation of cytochrome P450/cyclo-phosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 57, 4830ā4837.
Kim, Y. G., Bi, W., Feliciano, E. S., Drake, R. R., and Stambrook, P. J. (2000) Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase. Cancer Gene Ther. 7, 240ā246.
Kammertoens, T., Gelbmann, W., Karle, P., et al. (2000) Combined chemotherapy of murine mammary tumors by local activationof the prodrug ifosfamide and 5-fluorocytosine. Cancer Gene Ther. 7, 629ā636.
Rogulski, K. R., Wing, M. S., Paielli, D. L., Gilbert, J. D., Kim J. H., and Freytag, S. O. (2000) Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Human Gene Ther. 11, 67ā76.
Toda, M., Martuza, R. L., and Rabkin, S. D. (2001) Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 8, 332ā339.
Candotti, F., Agbaria, R., Mullen, C. A., et al. (2000) Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene therapy. Cancer Gene Ther. 7, 574ā580.
Thust, R., Tomicic, M., Klocking, R., Voutilainen, N., Wutzler, P., and Kaina, B. (2000) Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implication for gene therapeutic approaches. Cancer Gene Ther. 7, 107ā117.
Hasegawa, Y., Nishiyama, Y., Imaizumi, K., et al. (2000) Avoidance of bone marrow suppression using A-5021 as a nucleoside analog for retrovirus-mediated herpes simplex virus type I thymidine kinase gene therapy. Cancer Gene Ther. 7, 557ā562.
Hayashi, K., Hayashi, T., Sun, H.-D., and Takeda, I. (2000) Potentiation of ganciclovir toxicity in the herpes simplex virus thymidine kinase/ganciclovir administration system by ponicidin. Cancer Gene Ther. 7, 45ā42.
McMasters, R. A., Wilbert, T. N., Jones, K. E., et al. (2000) Two-drug combinations that increase apoptosis and modulate Bak and Bcl-Xl expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase. Cancer Gene Ther. 7, 563ā573.
Rubsam, L. Z., Davidson, L., and Shewach, D. S. (1998) Superior cytotoxicity with gancyclovir compared with acyclovir and 1-Ī²-d-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing-cells: a novel paradigm for cell killing. Cancer Res. 58, 3873ā3882.
Boucher, P. D., Ostruszka, L. J., and Shewach, D. S. (2000) Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir mediated cytotoxicity by hydroxyurea. Cancer Res. 60, 1631ā1636.
Huang, Z., Raychowdhury, K., and Waxman, D. J. (2000) Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrom P450-based cancer gene therapy model. Cancer Gene Ther. 7, 1034ā1042.
Jounaidi, Y. and Waxman, D. J. (2000) Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 60, 3761ā3769.
Kanyama, H., Tomita, N., Yamano, T., et al. (2001) Usefulness of repeated intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res. 61, 14ā18.
Jounaidi, Y. and Waxman, D. J. (2001) Frequent, moderate dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase based cancer gene therapy. Cancer Res. 61, 4437ā4444.
Brust, D., Feden, J., Farnsworth, J., Amir, C., Broaddus, W. C., and Valerie, K. (2000) Radiosensitization of rat glioma with bromodeoxycytidine and adenovirus expressing herpes simplex virus-thymidine kinase delivered by slow, rate-controlled positive pressure infusion. Cancer Gene Ther. 7, 778ā788.
Valerie, K., Brust, D., Farnsworth, J., et al. (2000) Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther. 7, 879ā884.
Valerie, K., Hawkins, W., Farnsworth, J., et al. (2001) Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther. 8, 3ā8.
Kawashita, Y., Ohtsuru, A., Kaneda, Y., et al. (1999) Regression of hepatocelluar carcinoma in vitro and in vivo by radiosensitising suicide gene therapy under the inducible and spatial control of radiation. Hum. Gene Ther. 10, 1509ā1519.
Nuyts, S., Theys, J., Landuyt, W., Van Mellaert, L., Lambin, P., and Anne, J. (2001) Increasing specificity of anti-tumour therapy: cytotoxic proteins delivery by non-pathogenic Clostridia under regulation of radio-induced promoter. Anticancer Res. 21, 857ā862.
Nuyts, S., Van Mellaert, L., Theys, J., Landuyt, W., Lambin, P., and Anne, J. (2001) The use of radiation-induced bacterial promoters in anaerobic-conditions: a means to control gene expression in Clostridium-mediated gene therapy. Radiat. Res. 155, 716ā723.
Steffens, S., Frank, S., Fisher, U., et al. (2000) Enhanced green fluorescent proteinfusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy. Cancer Gene Ther. 7, 806ā812.
Tjuvajev, J.G., Finn, R., Watanabe, K., et al. (1996) Noninvasive imaging of herpes simplex virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res. 56, 4087ā4095.
Tjuvajev, J.G., Avril, N., Oku, T., et al. (1998) Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 58, 4333ā4341.
Yagoubi, S. S., Wu, L., Liang, Q., et al. (2001) Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors. Gene Ther. 8, 1072ā1080.
Brust, P., Haubner, R., Friedrich, A., et al. (2001) Comparison of [18F]FHPG and [124/125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur. J. Nucl. Med 28, 721ā729.
Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. (1994) Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91, 8302ā8306.
Imaizumi, K., Hasegawa, Y., Kawabe, T., Emi, N., Saito, H., Naruse, K., and Shimokata, K. (1998) Bystander tumoricidal effect and gap junctional communication in lung cancer cells. Am. J. Respir. Cell Mol. Biol. 18, 205ā212.
Wygoda, M. R., Wilson, M. R., Davis, M. A., Trosko, J. E., Rehemtulla, A., and Lawrence, T. S. (1997) Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicityby bystander cells: the good Samaritan effect. Cancer Res. 57, 1699ā1703.
Andrade-Rosental, A. F., Rosental, R., Hopperstad, M. D., Wu, J. K., Vrionis, F. D., and Spray, D. C. (2000) Gap junctions: the ākiss of deathā and the ākiss of life.ā Brain Res. Rev. 32, 308ā315.
Touraine, R. L., Vahanian, N., Ramsey, W. J., and Blaese, R. M. (1998) Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9, 2385ā2391.
Touraine, R. L., Ishii-Morita, H., Ramsey, W. J., and Blaese, R. M. (1998) The bystander effect in the HSVtk/ganciclovir system and its relation to gap junctional communication. Gene Ther. 5, 1705ā1711.
Grignet-Debrus, C., Cool, V., Baudson, N., Velu, T., and Calberg-Bacq, C.-M. (2000) The role of cellular-and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy. Cancer Gene Ther. 7, 1456ā1468.
Kaneko, Y. and Tsukamoto, A. (1995) Gene therapy of hepatoma: bystander effect s and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett. 96, 105ā110.
Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. (1996) In vivo analysis of the ābystander effectā: a cytokine cascade. Exp. Hematol. 24, 829ā838.
Agard, C., Ligeza, C., Dupas, B., et al. (2001) Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther. 8, 128ā136.
Majumdar, A., Zolotorev, A., Samuel, S., et al. (2000) Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 7, 1086ā1099.
Cao, X., Huang, X., Ju, D.W., Zhang, W.P., Hamada, H., and Wang, J. (2000) Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte macrophage colony-stimulating factor gene transfer. Cancer Gene Ther. 7, 177ā186.
Rivas, C., Chandler, P., Melo, J. V., Simpson, E., and Apperley, J. F. (2000) Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T-lymphoma. Cancer Gene Ther. 7, 954ā962.
Karle, P., Renner, M., Salmons, B., and Gunzburg, W. H. (2001) Necrotic, rather than apoptotic death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. 8, 220ā230.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Niculescu-Duvaz, I., Springer, C.J. (2004). Introduction to the Background, Principles, and State of the Art in Suicide Gene Therapy. In: Springer, C.J. (eds) Suicide Gene Therapy. Methods in Molecular Medicineā¢, vol 90. Humana Press. https://doi.org/10.1385/1-59259-429-8:1
Download citation
DOI: https://doi.org/10.1385/1-59259-429-8:1
Publisher Name: Humana Press
Print ISBN: 978-0-89603-971-1
Online ISBN: 978-1-59259-429-0
eBook Packages: Springer Protocols